RxDoctor Payments DataLook up a doctor →

Alexander Mule, PA

Physician Assistant · Costa Mesa, CANPI 1649744665

Payments from drug & device makers

$29,479in general payments, 2019–2025

Across 1,258 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$4K
  • Teva Pharmaceuticals USA, Inc.$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
  • Neurocrine Biosciences, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • plus $11K from 31 others

What the payments were for

  • Travel & lodging$90%
  • Food & beverage$29,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,479 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$22,778
Medicare patients
48
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$79,689
AustedoDeutetrabenazine11$54,787
CaplytaLumateperone Tosylate16$27,152
AuvelityDextromethorphan Hbr/Bupropion20$25,670
RexultiBrexpiprazole17$25,164
TrintellixVortioxetine Hydrobromide42$21,428
VraylarCariprazine Hcl13$19,684
Quetiapine Fumarate252$2,786
Aripiprazole85$2,380
Duloxetine Hcl93$1,920
Paliperidone ErPaliperidone12$1,449
Mirtazapine61$866
Olanzapine38$847
Trazodone Hcl105$822
Hydroxyzine Hcl34$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$3,107$134,47627 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$3,074$27,15216 claims
Axsome Therapeutics, Inc.Auvelity$747$25,67020 claims
Otsuka America Pharmaceutical, Inc.Rexulti$2,026$25,16417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$958$21,42842 claims
AbbVieVraylar$4,056$19,68413 claims
Almatica Pharma LLCSertraline Hcl$345$33091 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →